Fosamax Cost in Montana 2026: Alendronate Prices, Medicaid, and Your Cheapest Options

What Does Fosamax Actually Cost in Montana in 2026?

Generic alendronate at Montana retail pharmacies runs about $15 per month for the standard once-weekly 70 mg tablet, making it one of the more accessible bone-density drugs available. Brand-name Fosamax carries a manufacturer list price near $80 per month, but the vast majority of prescriptions filled in Montana today are generic.

The gap between brand and generic is not trivial. Alendronate's key patent expired years ago, and the FDA currently lists multiple approved generic manufacturers. A patient paying cash for brand-name Fosamax at a Billings or Missoula pharmacy could spend more than five times what the generic costs for identical pharmacology.

Prices vary by pharmacy. A 4-tablet (28-day) supply of alendronate 70 mg has been quoted as low as $11 at some Walmart and Costco locations in Montana and as high as $22 at independent rural pharmacies with lower dispensing volume. Calling ahead or using a GoodRx coupon before presenting at the counter remains the fastest way to confirm today's shelf price.

The Fracture Intervention Trial (FIT, JAMA 1998, N=2,027) demonstrated that alendronate reduced the relative risk of hip fracture by 47% and vertebral fracture by 44% over 3 years compared with placebo in women with low femoral-neck bone density [1]. That evidence base is why national guidelines recommend alendronate as a first-line oral option for postmenopausal osteoporosis. The American Association of Clinical Endocrinology (AACE) 2020 guidelines list alendronate among the preferred agents when cost is a barrier to therapy [2].

Does Montana Medicaid Cover Fosamax?

Montana Medicaid does not currently cover Fosamax or its generic alendronate on its preferred drug list for osteoporosis in 2025 to 2026. This leaves many low-income Montana patients without a straightforward reimbursement path for the drug.

Medicaid formularies change annually. A prior-authorization request citing documented osteoporosis (T-score at or below -2.5 on DEXA) plus a physician attestation of medical necessity has succeeded in getting some bisphosphonates covered in neighboring states with similar formulary structures, so it remains worth attempting. Montana's Medicaid drug-coverage inquiries go through the Department of Public Health and Human Services (DPHHS) at 406-444-4540.

Patients whose income places them above Medicaid thresholds but below 250% of the federal poverty level may qualify for the Merck Patient Assistance Program (PAP), which provides brand-name Fosamax at no cost. Merck's PAP enrollment is handled directly through their manufacturer portal and requires a valid Montana prescription.

For patients on Medicare Part D, coverage depends on the specific plan's formulary. Most Part D plans in Montana place generic alendronate on Tier 1 or Tier 2, with copays ranging from $0 to $10 per month after the deductible phase. The Medicare Plan Finder at medicare.gov allows a side-by-side comparison of Montana Part D plans and their exact alendronate cost-sharing for the plan year.

Compounded Alendronate in Montana: Legality and Cost

Compounded alendronate is legal in Montana when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. The compound must not be a copy of a commercially available product and requires documented clinical need.

Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353a) permits patient-specific compounding by licensed pharmacists acting on a prescription from a licensed practitioner [3]. Montana's Board of Pharmacy enforces these rules in parallel with federal FDA oversight. A 503A pharmacy in Montana cannot produce bulk, anticipatory quantities of alendronate without running into federal manufacturing law, but one-off compounded preparations for an individual patient are permissible.

Why would a clinician write for compounded alendronate instead of the generic tablet? The generic 70 mg oral tablet is insoluble and must be taken with 8 ounces of plain water, 30 minutes before any food or other medication, while the patient stays upright. Patients who cannot tolerate this regimen due to esophageal motility disorders, GERD, or physical frailty preventing sustained upright positioning sometimes benefit from an alternative dosage form. Compounded preparations can include oral solutions or different concentrations. Cost for qualifying patients through some 503A programs runs as low as $0 per month when paired with a clinical subsidy program.

Confirm that any Montana compounding pharmacy you use is licensed by the Montana Board of Pharmacy and that the prescribing clinician is licensed in Montana. HealthRX verifies both before routing a compounding order.

Which Insurance Plans Cover Fosamax in Montana?

Most commercial insurance plans operating in Montana cover generic alendronate. Coverage details differ by plan tier and deductible structure.

Blue Cross Blue Shield of Montana (now Mountain Health CO-OP and affiliated plans), PacificSource Montana, and SelectHealth Montana all place generic alendronate on their generic-preferred Tier 1 or Tier 2 formulary positions for the 2025 to 2026 plan year, typically with a $5 to $15 copay after deductible. Brand-name Fosamax, when covered at all, usually lands on Tier 3 or Tier 4, resulting in copays of $40 to $90 per fill.

Employer-sponsored self-insured plans operating in Montana follow their own pharmacy benefit manager (PBM) formularies. Express Scripts, CVS Caremark, and OptumRx each list generic alendronate as preferred on their national formularies, which passes through to most Montana employer plans. A benefits coordinator or the number on the back of your insurance card can confirm the exact tier and copay.

Prior authorization is rarely required for generic alendronate on commercial plans, but it may be triggered if the prescriber writes brand-name Fosamax and the plan requires a step-through generic trial. In practice, prescribing generic first eliminates that barrier entirely.

How to Get the Cheapest Alendronate in Montana: A Step-by-Step Framework

Finding the lowest price takes 10 minutes of structured effort. Here is the decision path HealthRX clinicians use when counseling Montana patients on cost:

Step 1. Confirm the diagnosis warrants treatment. Alendronate is indicated for T-score at or below -2.5, or T-score between -1.0 and -2.5 with a 10-year major osteoporotic fracture probability at or above 20% per the FRAX tool (World Health Organization fracture-risk assessment model) [4]. Without a DEXA scan result in hand, ordering one through a Montana telehealth visit is the first clinical step.

Step 2. Check GoodRx before you leave the clinic. Entering "alendronate 70 mg, 4 tablets, Montana" into GoodRx at time of writing returns prices between $11 and $22 at Montana pharmacies. GoodRx coupons are not insurance; they are discount contracts and cannot be combined with insurance, but they often beat insured copays for generic alendronate.

Step 3. Run your insurance formulary. Log into your insurer's member portal and search "alendronate 70 mg." If the drug is Tier 1 or Tier 2, your copay likely beats GoodRx. If the drug is on Tier 3 or higher, use GoodRx or request a formulary exception citing AACE 2020 guidelines for preferred agent status [2].

Step 4. Apply for Merck's PAP if uninsured or underinsured. Income documentation required. Processing takes 2 to 4 weeks for initial approval.

Step 5. Ask your HealthRX clinician about 503A compounding. Patients with a documented clinical reason to avoid the standard oral tablet formulation may qualify. Cost may be substantially lower or zero through subsidy programs.

Step 6. Check Montana SHIP (State Health Insurance Assistance Program). Montana SHIP (406-800-3855) offers free counseling on Medicare Part D plan selection and can identify which plans carry alendronate at the lowest copay in your county.

Telehealth Alendronate Prescribing in Montana

Telehealth prescribing of alendronate is legal in Montana. Montana Code Annotated Title 37 permits audio-video telemedicine encounters as the basis for a valid physician-patient relationship, and non-controlled prescription drugs like alendronate can be prescribed following a synchronous telehealth visit without a prior in-person examination.

A HealthRX visit for alendronate initiation takes approximately 20 minutes. The clinician reviews your most recent DEXA report, fracture history, renal function (alendronate is contraindicated when creatinine clearance is below 35 mL/min), and current medication list for interactions. If DEXA data is more than 2 years old, the clinician will order a new scan through a Montana-based imaging center before starting therapy.

The FDA-approved label for alendronate specifies that patients must be able to sit or stand upright for at least 30 minutes after ingestion to minimize esophageal irritation risk [5]. Patients with active esophageal disease, Barrett's esophagus, or an inability to comply with this posturing requirement should discuss alternative bisphosphonate formulations (intravenous zoledronic acid, for example) or different drug classes with their clinician during the visit.

Montana telehealth prescriptions are transmitted electronically to any Montana-licensed pharmacy or to a mail-order pharmacy licensed to operate in Montana. Turnaround from visit to medication in hand is typically 24 to 72 hours for retail pharmacy and 5 to 7 business days for mail order.

Clinical Pharmacology: What Alendronate Does and Why It Matters

Alendronate is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. It binds to hydroxyapatite in bone mineral and selectively impairs the enzyme farnesyl pyrophosphate synthase in osteoclasts, reducing bone turnover [6].

Bioavailability is low. Oral absorption is approximately 0.7% of the administered dose under fasting conditions. Taking the tablet with coffee, orange juice, or any food reduces absorption by 60% or more, which is why the 30-minute fasting window is non-negotiable clinically, not just a label formality.

The FIT trial, the largest placebo-controlled bisphosphonate trial to date, enrolled 2,027 postmenopausal women with femoral-neck T-scores at or below -1.6 [1]. At 3 years, alendronate 10 mg daily (equivalent in antifracture efficacy to 70 mg once weekly, the current standard) reduced:

• Hip fracture risk by 47% (relative risk 0.53 to 95% CI 0.31, 0.90, P<0.05)
• Vertebral fracture risk by 44% (RR 0.56 to 95% CI 0.39, 0.80, P<0.001)
• Wrist fracture risk by 26% (RR 0.74 to 95% CI 0.52, 1.04, though this reached statistical significance in a pooled analysis)

The National Osteoporosis Foundation's "Clinician's Guide to Prevention and Treatment of Osteoporosis" states: "Bisphosphonates are the most widely prescribed class of osteoporosis medications and have been shown in randomized controlled trials to significantly reduce fracture risk" [7].

Once-weekly alendronate 70 mg and daily 10 mg produce equivalent lumbar spine bone-mineral density gains at 1 year (mean 6.8% vs. 7.1%, respectively), making the weekly formulation the preferred choice for adherence across most clinical settings [8].

Drug Holidays and Duration of Therapy

Treatment duration is a frequent question in telehealth visits. After 3 to 5 years of alendronate therapy, clinicians should reassess fracture risk to determine whether a drug holiday is appropriate.

The FLEX trial (N=1,099) found that women who continued alendronate for 10 years had a lower risk of clinical vertebral fractures compared with those who stopped at 5 years, but hip-fracture risk did not differ significantly between the groups at low-to-moderate baseline risk [9]. For patients with femoral-neck T-score above -2.5 after 5 years and no incident fractures, a 2-to-3-year drug holiday is reasonable per AACE guidance. Patients with T-score at or below -2.5 or prior vertebral fractures should generally continue.

During a drug holiday, alendronate persists in bone mineral and continues to suppress bone turnover for 12 to 24 months after discontinuation. Biochemical markers of bone resorption (serum CTX, urine NTX) can monitor the return of resorption activity and help time re-initiation.

Monitoring Requirements While on Alendronate in Montana

Baseline and follow-up monitoring keeps therapy both safe and effective. Every new alendronate patient needs:

• DEXA scan at baseline. Montana imaging centers in Billings, Great Falls, Missoula, Bozeman, and Kalispell offer DEXA. HealthRX can order these statewide via telehealth referral.
• Serum creatinine and estimated GFR. Alendronate is contraindicated at creatinine clearance below 35 mL/min. For patients over 65 or with diabetes, check creatinine before prescribing.
• Serum calcium and 25-hydroxyvitamin D. Hypocalcemia must be corrected before starting any bisphosphonate. Many Montana patients are vitamin D-deficient due to the state's latitude and long winters; supplementation with at least 800 to 1 to 000 IU vitamin D3 daily plus 1,000 to 1 to 200 mg elemental calcium (diet plus supplement combined) should accompany alendronate [7].
• DEXA at 1 to 2 years. A meaningful change in bone mineral density is typically visible by 24 months of consistent therapy.
• Dental evaluation. Osteonecrosis of the jaw (ONJ) is a rare but documented risk, most significant in patients receiving high-dose IV bisphosphonates for cancer indications. Oral alendronate at osteoporosis doses carries a very low ONJ risk (estimated 1 in 10,000 to 1 in 100,000 patient-years) [10], but patients should disclose bisphosphonate use before any dental extraction.

Atypical femoral fracture is a second rare adverse event associated with long-term bisphosphonate use. Thigh or groin pain without trauma in a patient on alendronate for more than 5 years warrants an X-ray of the full femur. The FDA added a class warning for this in 2010 [5].

The American Society for Bone and Mineral Research (ASBMR) task force report concludes: "The benefits of bisphosphonate therapy in reducing fracture risk far outweigh the risk of atypical femoral fracture for most patients, particularly in the first 3 to 5 years of treatment" [10].